Current challenges and future directions in the management of ovarian cancer

Proceedings of the first global workshop on ovarian cancer

J. Tate Thigpen, David S Alberts, Michael Birrer, Larry Copeland, Robert L. Coleman, Maurie Markman, Robert C. Bast, Eric L. Eisenhauer, Gini Fleming, Paula M. Fracasso, David M. Gershenson, Thomas Herzog, Bradley J. Monk, Robert F. Ozols, Gordon Rustin, Mark F. Brady, Marissa Shrader, Aarati Ranganathan

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Epithelial ovarian cancer is the leading cause of death from gynecologic malignancies in the United States. Although the prevalence of ovarian cancer when compared with other neoplasms is low, with an estimated 21,550 new cases in 2009, the majority of patients are diagnosed at an advanced stage of disease, with projected 5-year relative survival rates of 31%. Early detection is a clinically relevant goal for the optimal management of patients with ovarian cancer. Attempts to develop valuable screening strategies and incorporate preventive measures are ongoing. Frontline management of ovarian cancer involves primary cytoreductive surgery followed by platinum-based combination chemotherapy and up to 80% of women with advanced disease achieve an objective response and 10%-20% are cured with this regimen; nevertheless, disease recurrence is inevitable in most patients. Multiple strategies including the inclusion of effective targeted therapies upfront and the incorporation of maintenance regimens are being investigated to improve frontline response rates. Currently, the choice of treatment in recurrent ovarian cancer is based on the disease-free interval from completion of frst-line platinum-based therapy; several platinum and non-platinum agents are used in the recurrent setting with equivalent effcacy outcomes. The roles of targeted therapies, secondary cytoreductive surgery, and rising cancer antigen 125 levels in the treatment of recurrent disease are being delineated. Clearly, there is a need to identify novel agents and personalized strategies that will improve clinical outcomes in this disease. It is likely that a better understanding of the molecular changes in the pathogenesis of ovarian cancer will pave the way for more effective therapeutic options. This summary highlights current challenges in the management of ovarian cancer and outlines expert perspectives, key questions, and future directions.

Original languageEnglish (US)
Pages (from-to)81-97
Number of pages17
JournalClinical Ovarian Cancer
Volume3
Issue number2
DOIs
StatePublished - Nov 2010

Fingerprint

Ovarian Neoplasms
Education
Platinum
Therapeutics
Neoplasms
Combination Drug Therapy
Direction compound
Cause of Death
Survival Rate
Maintenance
Antigens
Recurrence

Keywords

  • Bevacizumab
  • CA-125
  • Cediranib
  • Pazopanib

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology

Cite this

Current challenges and future directions in the management of ovarian cancer : Proceedings of the first global workshop on ovarian cancer. / Thigpen, J. Tate; Alberts, David S; Birrer, Michael; Copeland, Larry; Coleman, Robert L.; Markman, Maurie; Bast, Robert C.; Eisenhauer, Eric L.; Fleming, Gini; Fracasso, Paula M.; Gershenson, David M.; Herzog, Thomas; Monk, Bradley J.; Ozols, Robert F.; Rustin, Gordon; Brady, Mark F.; Shrader, Marissa; Ranganathan, Aarati.

In: Clinical Ovarian Cancer, Vol. 3, No. 2, 11.2010, p. 81-97.

Research output: Contribution to journalArticle

Thigpen, JT, Alberts, DS, Birrer, M, Copeland, L, Coleman, RL, Markman, M, Bast, RC, Eisenhauer, EL, Fleming, G, Fracasso, PM, Gershenson, DM, Herzog, T, Monk, BJ, Ozols, RF, Rustin, G, Brady, MF, Shrader, M & Ranganathan, A 2010, 'Current challenges and future directions in the management of ovarian cancer: Proceedings of the first global workshop on ovarian cancer', Clinical Ovarian Cancer, vol. 3, no. 2, pp. 81-97. https://doi.org/10.3816/COC.2010.n.015
Thigpen, J. Tate ; Alberts, David S ; Birrer, Michael ; Copeland, Larry ; Coleman, Robert L. ; Markman, Maurie ; Bast, Robert C. ; Eisenhauer, Eric L. ; Fleming, Gini ; Fracasso, Paula M. ; Gershenson, David M. ; Herzog, Thomas ; Monk, Bradley J. ; Ozols, Robert F. ; Rustin, Gordon ; Brady, Mark F. ; Shrader, Marissa ; Ranganathan, Aarati. / Current challenges and future directions in the management of ovarian cancer : Proceedings of the first global workshop on ovarian cancer. In: Clinical Ovarian Cancer. 2010 ; Vol. 3, No. 2. pp. 81-97.
@article{6cfe701f9027438987dec0ae52ff08bb,
title = "Current challenges and future directions in the management of ovarian cancer: Proceedings of the first global workshop on ovarian cancer",
abstract = "Epithelial ovarian cancer is the leading cause of death from gynecologic malignancies in the United States. Although the prevalence of ovarian cancer when compared with other neoplasms is low, with an estimated 21,550 new cases in 2009, the majority of patients are diagnosed at an advanced stage of disease, with projected 5-year relative survival rates of 31{\%}. Early detection is a clinically relevant goal for the optimal management of patients with ovarian cancer. Attempts to develop valuable screening strategies and incorporate preventive measures are ongoing. Frontline management of ovarian cancer involves primary cytoreductive surgery followed by platinum-based combination chemotherapy and up to 80{\%} of women with advanced disease achieve an objective response and 10{\%}-20{\%} are cured with this regimen; nevertheless, disease recurrence is inevitable in most patients. Multiple strategies including the inclusion of effective targeted therapies upfront and the incorporation of maintenance regimens are being investigated to improve frontline response rates. Currently, the choice of treatment in recurrent ovarian cancer is based on the disease-free interval from completion of frst-line platinum-based therapy; several platinum and non-platinum agents are used in the recurrent setting with equivalent effcacy outcomes. The roles of targeted therapies, secondary cytoreductive surgery, and rising cancer antigen 125 levels in the treatment of recurrent disease are being delineated. Clearly, there is a need to identify novel agents and personalized strategies that will improve clinical outcomes in this disease. It is likely that a better understanding of the molecular changes in the pathogenesis of ovarian cancer will pave the way for more effective therapeutic options. This summary highlights current challenges in the management of ovarian cancer and outlines expert perspectives, key questions, and future directions.",
keywords = "Bevacizumab, CA-125, Cediranib, Pazopanib",
author = "Thigpen, {J. Tate} and Alberts, {David S} and Michael Birrer and Larry Copeland and Coleman, {Robert L.} and Maurie Markman and Bast, {Robert C.} and Eisenhauer, {Eric L.} and Gini Fleming and Fracasso, {Paula M.} and Gershenson, {David M.} and Thomas Herzog and Monk, {Bradley J.} and Ozols, {Robert F.} and Gordon Rustin and Brady, {Mark F.} and Marissa Shrader and Aarati Ranganathan",
year = "2010",
month = "11",
doi = "10.3816/COC.2010.n.015",
language = "English (US)",
volume = "3",
pages = "81--97",
journal = "Clinical Ovarian Cancer",
issn = "2212-9553",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Current challenges and future directions in the management of ovarian cancer

T2 - Proceedings of the first global workshop on ovarian cancer

AU - Thigpen, J. Tate

AU - Alberts, David S

AU - Birrer, Michael

AU - Copeland, Larry

AU - Coleman, Robert L.

AU - Markman, Maurie

AU - Bast, Robert C.

AU - Eisenhauer, Eric L.

AU - Fleming, Gini

AU - Fracasso, Paula M.

AU - Gershenson, David M.

AU - Herzog, Thomas

AU - Monk, Bradley J.

AU - Ozols, Robert F.

AU - Rustin, Gordon

AU - Brady, Mark F.

AU - Shrader, Marissa

AU - Ranganathan, Aarati

PY - 2010/11

Y1 - 2010/11

N2 - Epithelial ovarian cancer is the leading cause of death from gynecologic malignancies in the United States. Although the prevalence of ovarian cancer when compared with other neoplasms is low, with an estimated 21,550 new cases in 2009, the majority of patients are diagnosed at an advanced stage of disease, with projected 5-year relative survival rates of 31%. Early detection is a clinically relevant goal for the optimal management of patients with ovarian cancer. Attempts to develop valuable screening strategies and incorporate preventive measures are ongoing. Frontline management of ovarian cancer involves primary cytoreductive surgery followed by platinum-based combination chemotherapy and up to 80% of women with advanced disease achieve an objective response and 10%-20% are cured with this regimen; nevertheless, disease recurrence is inevitable in most patients. Multiple strategies including the inclusion of effective targeted therapies upfront and the incorporation of maintenance regimens are being investigated to improve frontline response rates. Currently, the choice of treatment in recurrent ovarian cancer is based on the disease-free interval from completion of frst-line platinum-based therapy; several platinum and non-platinum agents are used in the recurrent setting with equivalent effcacy outcomes. The roles of targeted therapies, secondary cytoreductive surgery, and rising cancer antigen 125 levels in the treatment of recurrent disease are being delineated. Clearly, there is a need to identify novel agents and personalized strategies that will improve clinical outcomes in this disease. It is likely that a better understanding of the molecular changes in the pathogenesis of ovarian cancer will pave the way for more effective therapeutic options. This summary highlights current challenges in the management of ovarian cancer and outlines expert perspectives, key questions, and future directions.

AB - Epithelial ovarian cancer is the leading cause of death from gynecologic malignancies in the United States. Although the prevalence of ovarian cancer when compared with other neoplasms is low, with an estimated 21,550 new cases in 2009, the majority of patients are diagnosed at an advanced stage of disease, with projected 5-year relative survival rates of 31%. Early detection is a clinically relevant goal for the optimal management of patients with ovarian cancer. Attempts to develop valuable screening strategies and incorporate preventive measures are ongoing. Frontline management of ovarian cancer involves primary cytoreductive surgery followed by platinum-based combination chemotherapy and up to 80% of women with advanced disease achieve an objective response and 10%-20% are cured with this regimen; nevertheless, disease recurrence is inevitable in most patients. Multiple strategies including the inclusion of effective targeted therapies upfront and the incorporation of maintenance regimens are being investigated to improve frontline response rates. Currently, the choice of treatment in recurrent ovarian cancer is based on the disease-free interval from completion of frst-line platinum-based therapy; several platinum and non-platinum agents are used in the recurrent setting with equivalent effcacy outcomes. The roles of targeted therapies, secondary cytoreductive surgery, and rising cancer antigen 125 levels in the treatment of recurrent disease are being delineated. Clearly, there is a need to identify novel agents and personalized strategies that will improve clinical outcomes in this disease. It is likely that a better understanding of the molecular changes in the pathogenesis of ovarian cancer will pave the way for more effective therapeutic options. This summary highlights current challenges in the management of ovarian cancer and outlines expert perspectives, key questions, and future directions.

KW - Bevacizumab

KW - CA-125

KW - Cediranib

KW - Pazopanib

UR - http://www.scopus.com/inward/record.url?scp=79951935624&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79951935624&partnerID=8YFLogxK

U2 - 10.3816/COC.2010.n.015

DO - 10.3816/COC.2010.n.015

M3 - Article

VL - 3

SP - 81

EP - 97

JO - Clinical Ovarian Cancer

JF - Clinical Ovarian Cancer

SN - 2212-9553

IS - 2

ER -